MX2020000029A - Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon. - Google Patents

Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon.

Info

Publication number
MX2020000029A
MX2020000029A MX2020000029A MX2020000029A MX2020000029A MX 2020000029 A MX2020000029 A MX 2020000029A MX 2020000029 A MX2020000029 A MX 2020000029A MX 2020000029 A MX2020000029 A MX 2020000029A MX 2020000029 A MX2020000029 A MX 2020000029A
Authority
MX
Mexico
Prior art keywords
mussel adhesive
montelukast
combinations
topical formulations
adhesive proteins
Prior art date
Application number
MX2020000029A
Other languages
English (en)
Inventor
Bengt Ingeman SAMUELSSON
Ming Gu
Original Assignee
Jiangyin Mucocare Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangyin Mucocare Pharmaceutical Co Ltd filed Critical Jiangyin Mucocare Pharmaceutical Co Ltd
Publication of MX2020000029A publication Critical patent/MX2020000029A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan formulaciones farmacéuticas tópicas que comprenden montelukast, o una sal farmacéuticamente aceptable de solvato de este, así como productos combinados que comprenden (a) al menos una proteína adhesiva del mejillón o un derivado de esta; y (b) montelukast, o una sal o solvato farmacéuticamente aceptable de este. Las formulaciones y los productos combinados encuentran una utilidad particular en la administración tópica directa para el tratamiento de la inflamación, de los trastornos inflamatorios y/o de afecciones caracterizadas por la inflamación, que incluyen heridas, quemaduras, psoriasis, acné y dermatitis atópica.
MX2020000029A 2017-07-05 2018-07-04 Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon. MX2020000029A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017091819 2017-07-05
CN2018087058 2018-05-16
PCT/CN2018/094441 WO2019007356A1 (en) 2017-07-05 2018-07-04 TOPICAL FORMULATIONS COMPRISING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS

Publications (1)

Publication Number Publication Date
MX2020000029A true MX2020000029A (es) 2020-08-06

Family

ID=64949737

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000029A MX2020000029A (es) 2017-07-05 2018-07-04 Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon.

Country Status (12)

Country Link
US (2) US11672792B2 (es)
EP (1) EP3648767A4 (es)
JP (1) JP7288404B2 (es)
KR (1) KR20200039677A (es)
CN (3) CN113491696A (es)
AU (1) AU2018295944B2 (es)
CA (1) CA3068818A1 (es)
MA (1) MA52924A (es)
MX (1) MX2020000029A (es)
SG (1) SG11201911841PA (es)
TW (1) TW201919633A (es)
WO (1) WO2019007356A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019007356A1 (en) * 2017-07-05 2019-01-10 Jiangyin Usun Pharmaceutical Co., Ltd. TOPICAL FORMULATIONS COMPRISING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS
EP4253404A3 (en) 2018-09-14 2023-12-13 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. Conjugates of montelukast and peptides
JP2022516729A (ja) * 2019-01-10 2022-03-02 ジャンイン ムコケア ファーマシューティカル カンパニー，リミテッド ロイコトリエン受容体アンタゴニストを含有する新たな製剤
WO2021047648A1 (en) * 2019-09-14 2021-03-18 Jiangyin Usun Pharmaceutical Co., Ltd. New peptides
AU2020397005A1 (en) * 2019-12-02 2022-06-23 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New multi-functional oligopeptides
KR20220116468A (ko) * 2019-12-02 2022-08-23 엔리티사 (상하이) 파마슈티컬 컴퍼니 리미티드 펩티드 및 다당류의 새로운 접합체
EP4099982A1 (en) 2020-02-03 2022-12-14 Taro Pharmaceutical Industries Ltd. Topical montelukast formulations
US20230372324A1 (en) 2020-10-13 2023-11-23 Diomed Developments Ltd. Gel formulations comprising montelukast
CN114588267A (zh) * 2020-12-04 2022-06-07 江苏恒瑞医药股份有限公司 一种含酰胺类局部麻醉药的药物组合物
WO2022193186A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New diagnostic and therapeutic agents
US20240165247A1 (en) * 2021-03-17 2024-05-23 Jiangyin Usun Pharmaceutical Co., Ltd. New peptide conjugates
AU2022323492A1 (en) * 2021-08-06 2024-03-21 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New treatment of immunodeficiency disorder
CN116421547A (zh) * 2023-03-09 2023-07-14 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种孟鲁司特钠外用乳膏剂的制备及其在炎症性皮肤病中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0812588T1 (en) * 1995-12-28 2005-02-28 Mitsubishi Pharma Corporation Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder
US20030207932A1 (en) 2002-05-03 2003-11-06 Morris Mann Compositions that prevent post-traumatic hyperpigmentation and methods related thereto
RU2358753C2 (ru) * 2003-08-07 2009-06-20 Хилор Лтд. Фармацевтические композиции и способы для ускорения заживления ран
US6987170B1 (en) * 2004-08-09 2006-01-17 Battelle Energy Alliance, Llc Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis
WO2007126865A2 (en) 2006-03-30 2007-11-08 Patrin Pharma Leukotriene antagonists via nasal drug delivery
CN1961867A (zh) 2006-11-16 2007-05-16 徐英权 孟鲁司特钠的颗粒剂型
WO2008106081A1 (en) 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and use for treatment or prevention of capsular contracture, scarring or hyperpigmentation
WO2008105803A1 (en) * 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and uses thereof
US20110124681A1 (en) 2008-05-06 2011-05-26 Schlesinger Larry S Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof
CA2653011A1 (en) * 2008-12-03 2010-06-03 Apotex Technologies Inc Method and apparatus for packaging and dispensing pharmaceuticals
GB0915319D0 (en) 2009-09-03 2009-10-07 Sharma Anant Combination medicament
CN101773503A (zh) 2010-01-12 2010-07-14 北京华禧联合科技发展有限公司 一种白三烯拮抗剂和抗组胺药组合物
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
CN102895661A (zh) * 2011-07-28 2013-01-30 中国科学院上海药物研究所 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
JP6200432B2 (ja) 2011-12-26 2017-09-20 エスケー ケミカルズ カンパニー リミテッド モンテルカストまたはその薬学的に許容可能な塩を含む経口投与用フィルム
CN103239450B (zh) 2012-02-07 2014-11-26 齐鲁制药有限公司 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法
AU2014249531B2 (en) * 2013-03-13 2018-11-29 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
CN103655497B (zh) 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 一种孟鲁司特钠口腔崩解片及其制备方法
CN105769825A (zh) 2014-12-24 2016-07-20 广州朗圣药业有限公司 一种孟鲁司特钠的口腔膜剂及其制备方法
CN105878215A (zh) 2014-12-31 2016-08-24 天津康鸿医药科技发展有限公司 一种稳定的孟鲁司特口腔速溶膜及其制备方法和用途
KR101892340B1 (ko) * 2015-03-13 2018-08-27 경희대학교 산학협력단 몬테루카스트의 생체이용률을 개선시키기 위한 방법
CN104784157B (zh) 2015-04-04 2018-06-26 齐鲁制药有限公司 一种稳定的孟鲁司特口腔薄膜剂
US10568938B2 (en) * 2015-07-20 2020-02-25 Jiangyin Bengt I. Samuelsson Institute Of Life Science Co., Ltd. Mussel adhesive protein product and applications thereof in suppression of skin inflammations
WO2017011983A1 (zh) * 2015-07-20 2017-01-26 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白用于皮肤和皮肤附属器官的防护
US10548837B1 (en) 2016-05-04 2020-02-04 Taro Pharmaceutical Industries Ltd. Topical montelukast for treatment of atopic dermatitis
WO2019007356A1 (en) * 2017-07-05 2019-01-10 Jiangyin Usun Pharmaceutical Co., Ltd. TOPICAL FORMULATIONS COMPRISING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS
MA52794A (fr) * 2018-05-28 2021-04-14 Jiangyin Usun Pharmaceutical Co Ltd Nouvelle utilisation pharmaceutique
EP4253404A3 (en) * 2018-09-14 2023-12-13 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. Conjugates of montelukast and peptides
JP2022516729A (ja) * 2019-01-10 2022-03-02 ジャンイン ムコケア ファーマシューティカル カンパニー，リミテッド ロイコトリエン受容体アンタゴニストを含有する新たな製剤

Also Published As

Publication number Publication date
EP3648767A4 (en) 2021-04-28
CN115300508A (zh) 2022-11-08
CN110312513A (zh) 2019-10-08
WO2019007356A1 (en) 2019-01-10
US11672792B2 (en) 2023-06-13
AU2018295944B2 (en) 2023-12-14
KR20200039677A (ko) 2020-04-16
AU2018295944A1 (en) 2020-02-20
JP2020527134A (ja) 2020-09-03
MA52924A (fr) 2021-04-28
SG11201911841PA (en) 2020-01-30
TW201919633A (zh) 2019-06-01
US20210145819A1 (en) 2021-05-20
CN113491696A (zh) 2021-10-12
US20230404992A1 (en) 2023-12-21
JP7288404B2 (ja) 2023-06-07
EP3648767A1 (en) 2020-05-13
CN110312513B (zh) 2022-07-08
CA3068818A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
MX2020000029A (es) Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon.
EP4230627A3 (en) Inhibitors of the menin-mll interaction
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
WO2018136264A9 (en) Pyridine compounds as allosteric shp2 inhibitors
PH12016501512B1 (en) Treatment for resistant acne
EP3451856A4 (en) METHOD FOR PRODUCING AND USING MYCELIED PROTEINARY FOOD COMPOSITIONS
EA202090948A1 (ru) Иммуномодуляция
EP3753936A4 (en) PYRIDONE DERIVATIVE, COMPOSITION THEREOF AND USE THEREOF AS AN AGAINST FLU MEDICATION
MX2016012262A (es) Cenicriviroc para el tratamiento de fibrosis.
EA201690093A1 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
EP3160493A4 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
MX2019001633A (es) Proteina derivada de la seda para el tratamiento de la inflamacion.
IL284125A (en) History of quinoline for use in the treatment of inflammatory diseases
EP3678701A4 (en) THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF
EP3303366A4 (en) DOLASTATIN DERIVATIVES AND USES THEREOF
EP4327828A3 (en) Solid forms of ceftolozane
EP3781576A4 (en) BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
EP3488850A4 (en) INNOVATIVE USE OF GZD824 AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF FOR THE TREATMENT OF DISEASES
EP3185695A4 (en) Preparation of soy protein products ("s810")
MX2017010277A (es) Cenicriviroc para el tratamiento de la fibrosis.
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
WO2020128070A3 (de) Kollagenhydrolysat zur verwendung gegen hautkrankheiten und darmkrankheiten